Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
CMC. Marcela Díaz‐MonteroMLMohamed L. SalemMIMichael I. NishimuraEGElizabeth Garrett‐MayerDJDavid J. Cole
Medical University of South Carolina · MUSC Hollings Cancer Center
Indexed incrossrefdoajpubmed
Abstract
No abstract available for this paper.
Citation impact
1,206
total citations
- FWCI
- 14.84
- Percentile
- 100%
- References
- 31
Citations per year
Authors
6- CMC. Marcela Díaz‐MonteroCorresponding
Medical University of South Carolina, MUSC Hollings Cancer Center
- MLMohamed L. Salem
MUSC Hollings Cancer Center, Medical University of South Carolina
- MIMichael I. Nishimura
MUSC Hollings Cancer Center, Medical University of South Carolina
- EGElizabeth Garrett‐Mayer
MUSC Hollings Cancer Center, Medical University of South Carolina
- DJDavid J. Cole
MUSC Hollings Cancer Center, Medical University of South Carolina
Topics & keywords
Topics
Keywords
- Medicine
- Cyclophosphamide
- Cancer
- Chemotherapy
- Myeloid-derived Suppressor Cell
- Doxorubicin
- Circulating tumor cell
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.